In addition, treatment with recombinant human LILRB4-extracellular domain-Fc fusion-protein has been shown to induce DC tolerance, reducing the progression of the disease, while blocking it exacerbated SLE (187). The gene discussed is LILRB4; the disease is systemic lupus erythematosus.